Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.50 |
| ▸ | CA1 | P00915 | 10/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676099 | 0.81 | CA2 (0.54) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL6676336 | 0.81 | ALDH1A1 (0.46) | CA2CA1NAMPTPTGER4KDM5B | |
| SCHEMBL6678526 | 0.80 | HTR6 (0.47) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL6693485 | 0.79 | CA2 (0.47) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL6679273 | 0.77 | CA2 (0.46) | CA2CA1NAMPTKMT2A | |
| SCHEMBL31748114 | 0.76 | CA2 (0.63) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL6676358 | 0.76 | CA2 (0.44) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL1185780 | 0.74 | CA2 (0.82) | CA2CA1CA12CA9 | |
| SCHEMBL31618968 | 0.74 | CA2 (0.63) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL1936202 | 0.73 | MGLL (0.55) | CA2CA1NAMPTKMT2ANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | CA2 696/4885CA1 2450/4885CA12 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.